EuroGentest Already Helping Patients Across Europe

Patients across the EU and associated states suffering from genetic conditions are already benefitting from work conducted within the framework of the EU-funded EuroGentest network of excellence (NoE), according to the network's coordinator and president elect of the European Society of Human Genetics (ESHG), Professor Jean-Jacques Cassiman. His comments were made during this year's European Human Genetics Conference, which ended on 3 June in Barcelona.

"One in 17 of us will suffer from a genetic disease," Professor Cassiman pointed out. "With the cost of diagnosis and treatment growing rapidly, genetic testing urgently needs to be harmonised across the EU. We in the genetics community - from geneticists to patient groups - realise this need and are united in the belief that Network of Excellence is the ideal vehicle to tackle the situation. Already through the unstinting efforts of our working parties and collaborators we have made major advances in our goal. Advances that are bringing immediate benefits to patients."

One of these achievements, according to Professor Cassiman, is the launch of a database in collaboration with Orpha.net, a partly EU-funded online portal for rare diseases and orphan drugs. The database contains information on laboratories that offer genetic testing, so that patients and their families can check the laboratories' credentials before entrusting them with a particular test.

"This is we believe essential since many of the diseases are extremely rare, specialist testing laboratories are often not local and may even be in different countries," Professor Cassiman explained. "In addition, genetic testing often results in considerable stress to patients and their families and so we have also produced a series of freely available patient information leaflets. Covering the main genetic disorders and the issues involved, they have been in great demand and been translated into nearly all community languages."

The director of the UK-based Genetic Interest Group (GIG), Alastair Kent, agrees that giving patients and their families access to information about laboratories is key, "Knowing that a lab is listed on a trusted site such as Orpha.net gives confidence in the validity of the results of genetic tests, and means that families are able to make better, more informed decisions. Equally having access to high quality patient information in your own language is also essential."

"These are, however, only outwardly visible examples," said Professor Cassiman, attributing large parts of EuroGentest's success to its organisation as a NoE. "Behind the scenes, our members have worked tirelessly and made major progress in encouraging and helping laboratories to adopt recognised quality management and accreditation schemes, as well as developing EQA [European quality assurance] schemes. [...] We have produced guidelines for counselling, surveys on patient rights and recommendations on patenting. All of this on a minimal and strictly audited budget."

The EuroGentest NoE was established at the beginning of 2005 by 32 partners under coordination of the Center for Human Genetics at the Catholic University Leuven in Belgium. With €10 million support from the EU's Sixth Framework Programme (FP6), it is set to run until the end of 2009, aiming primarily to improve and facilitate the genetic testing being done in laboratories across Europe.

According to EuroGentest, there are 1,500 centres in Europe that conduct genetic tests for about 1,000 different genetic conditions. The field is experiencing considerable growth in testing of 100 to 300% a year. About 30 million people in Europe suffer from genetic diseases, creating a cost to the EU health sector of approximately €500 million.

For further information, please visit:
http://www.eurogentest.org/

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

Great Start for Ideas and Innovations: D…

8 - 10 April 2025, Berlin, Germany. From 15 October to 15 November 2024, the DMEA invites experts from business, science, politics and practice to actively participate in shaping the congress...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...